pc:landm

Landmark Bio

300 N Beacon St Watertown, Massachusetts 02472, US

https://www.landmarkbio.com/

Research Platforms

Landmark Bio is a biotechnology company developing scalable manufacturing technologies for extracellular vesicles (EVs). The company focuses on building efficient continuous manufacturing platforms to support advanced therapies, including viral vectors and cell therapies.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―

Estimated Valuation―

Total Amount Raised$18M

Total Amount Raised$18M

Total Funding Rounds1

Total Funding Rounds1

Latest Funding Amount$18M

Latest Funding Amount$18M

Latest Funding RoundInvestment

Latest Funding RoundInvestment

Post-Money Valuation―

Post-Money Valuation―

Funding Round

Apr 16, 2026

Investment

$18.30M

―

Investors

Investment

Related News and Analysis

Landmark Bio – Weekly Recap

Landmark Bio – Weekly Recap

Landmark Bio – Weekly Recap Landmark Bio continued to sharpen its positioning as a cell and gene therapy-focused...

9d ago

Modular cGMP Infrastructure Underscores Landmark Bio’s Advanced Therapies CDMO Strategy

Modular cGMP Infrastructure Underscores Landmark Bio’s Advanced Therapies CDMO Strategy

A LinkedIn post from Landmark Bio highlights the company’s modular cGMP manufacturing suites designed to support a range...

11d ago

Landmark Bio Showcases rAAV Process Innovation and Technology Evaluation Role at NIIMBL 2026

Landmark Bio Showcases rAAV Process Innovation and Technology Evaluation Role at NIIMBL 2026

According to a recent LinkedIn post from Landmark Bio, the company plans to feature senior technical leadership at...

14d ago

Landmark Bio Showcases Synthetic DNA Gains and Rapid CAR-T Platform in Advanced Therapy Push

Landmark Bio Showcases Synthetic DNA Gains and Rapid CAR-T Platform in Advanced Therapy Push

Landmark Bio used a series of communications this week to spotlight advances in its cell and gene therapy...

16d ago

Landmark Bio Showcases Synthetic DNA Approach to Accelerate AAV Manufacturing

Landmark Bio Showcases Synthetic DNA Approach to Accelerate AAV Manufacturing

A LinkedIn post from Landmark Bio highlights recent testing of linear synthetic oDNA as an alternative to traditional...

17d ago

Landmark Bio Emphasizes Strategic CDMO Selection in Advanced Therapies

Landmark Bio Emphasizes Strategic CDMO Selection in Advanced Therapies

According to a recent LinkedIn post from Landmark Bio, the company is emphasizing the strategic importance of contract...

18d ago

Landmark Bio Emphasizes CMC Capabilities for In Vivo CAR-T Therapies

Landmark Bio Emphasizes CMC Capabilities for In Vivo CAR-T Therapies

According to a recent LinkedIn post from Landmark Bio, the company is drawing attention to in vivo CAR-T...

20d ago

Landmark Bio Highlights Integrated CDMO Model and Rapid CAR-T Platform in Focused Week

Landmark Bio Highlights Integrated CDMO Model and Rapid CAR-T Platform in Focused Week

Landmark Bio is spotlighting an integrated development and GMP manufacturing model as a core pillar of its contract...

23d ago

Integrated Development and GMP Model Highlights Landmark Bio’s CDMO Strategy

Integrated Development and GMP Model Highlights Landmark Bio’s CDMO Strategy

According to a recent LinkedIn post from Landmark Bio, the company emphasizes that its innovation and development labs...

25d ago

Landmark Bio Showcases Rapid CAR-T Manufacturing Workflow

Landmark Bio Showcases Rapid CAR-T Manufacturing Workflow

A LinkedIn post from Landmark Bio highlights an autologous CAR-T manufacturing workflow that is described as achievable in...

27d ago